Why Is REPLIMUNE GROUP INC (REPL) Stock Moving Today?

REPL stock is moving more than 100% in premarket trading after the U.S. Food and Drug Administration advisory committee voted in favor of Replimune’s RP1 therapy for advanced melanoma. The panel’s 10-3 decision supported the clinical meaningfulness of the drug’s efficacy, a key step toward potential regulatory approval. Analysts from Wedbush and Cantor Fitzgerald upgraded the stock following the outcome, citing improved odds of accelerated approval ahead of the August 2 FDA decision.

What Happened

Replimune’s shares opened at $12.68, a 134.3% increase from the previous close of $5.41. The FDA advisory panel’s positive vote has reinvigorated investor confidence in the company’s lead drug candidate. The panel’s backing suggests that RP1 may meet the regulatory standards necessary for approval, which could significantly alter the company’s trajectory. Cantor Fitzgerald noted that the outcome "materially improves the chances of accelerated approval," while Wedbush raised its price target to $12. The stock’s sharp rise reflects optimism that the therapy could soon move closer to market availability.

What The Data Shows

The stock is trading at $10.84 as of the latest update, with a session high of $12.97 and a low of $9.43. Volume has reached 14.2 million shares, more than double the 3-month average. The stock is currently trading near its 52-week high of $12.50. Despite the rally, the company remains unprofitable with an EPS TTM of -3.38 and a market cap of $449.2 million. The stock’s beta of 0.87 suggests it is slightly less volatile than the broader market. No unusual options activity or insider filings have been reported in the last 90 days.

What To Watch

Investors should monitor the FDA’s final decision on August 2, which will determine whether RP1 receives full approval. Analyst coverage is expected to remain active as the regulatory timeline becomes clearer.